Progress in oncolytic viruses modified with nanomaterials for intravenous application

Liting Chen; Zhijun Ma; Chen Xu; Youbang Xie; Defang Ouyang; Shuhui Song; Xiao Zhao; Funan Liu

doi:10.20892/j.issn.2095-3941.2023.0275

Progress in oncolytic viruses modified with nanomaterials for intravenous application

Cancer Biol Med. 2023 Nov 24;20(11):830-855. doi: 10.20892/j.issn.2095-3941.2023.0275.

Authors

Liting Chen^#^{1

2

3}, Zhijun Ma^#⁴, Chen Xu^{1

2

3}, Youbang Xie⁵, Defang Ouyang⁶, Shuhui Song^{1

2}, Xiao Zhao^{3

7

8}, Funan Liu^{1

2}

Affiliations

¹ Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
² Phase I Clinical Trials Center, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110102, China.
³ CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
⁴ Department of General Surgery, Panjin People's Hospital, Panjin 124221, China.
⁵ Department of Hematology and Rheumatology, Qinghai Provincial People's Hospital, Xining 810007, China.
⁶ State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau 999078, China.
⁷ Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.
⁸ IGDB-NCNST Joint Research Center, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China.

^# Contributed equally.

PMID: 38009779
PMCID: PMC10690878
DOI: 10.20892/j.issn.2095-3941.2023.0275

Abstract

In oncolytic virus (OV) therapy, a critical component of tumor immunotherapy, viruses selectively infect, replicate within, and eventually destroy tumor cells. Simultaneously, this therapy activates immune responses and mobilizes immune cells, thereby eliminating residual or distant cancer cells. However, because of OVs' high immunogenicity and immune clearance during circulation, their clinical applications are currently limited to intratumoral injections, and their use is severely restricted. In recent years, numerous studies have used nanomaterials to modify OVs to decrease virulence and increase safety for intravenous injection. The most commonly used nanomaterials for modifying OVs are liposomes, polymers, and albumin, because of their biosafety, practicability, and effectiveness. The aim of this review is to summarize progress in the use of these nanomaterials in preclinical experiments to modify OVs and to discuss the challenges encountered from basic research to clinical application.

Keywords: Oncolytic virus; drug delivery; intravenous application; nanomaterials; tumor treatment.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy
Neoplasms* / therapy
Oncolytic Virotherapy*
Oncolytic Viruses* / physiology

Abstract

Publication types

MeSH terms

Grants and funding